Surgical Site Infection Control Market Size is estimated to grow at a significant rate during 2022 to 2028 due to a rise in hospital-acquired infections and the number of surgeries. Positive clinical results linked with the usage of infection control will boost the industry growth.
Surgical site infection (SSI) occurs post-surgery in the body part where the surgery took place. SSIs remain one of the notable causes of mortality and morbidity, leading to readmissions to the hospital after surgery. Healthcare organizations are prioritizing SSI prevention following the rise in dental restoration, cataract surgery, and cesarean section. Industry players expect surgical- gloves, -scrubs, -drapes and disinfectants to be sought-after over 2022-2028.
Based on surgery/procedure, surgical site infection control market from cesarean section will grow owing to increased maternal mortality rate and longer hospital stays. SSI has become a common complication for the dissatisfaction of patients and higher treatment costs. According to the WHO, cesarean section accounts for over 21% of all childbirths globally and could rise to 29% by 2030. A soaring number of preterm births, cultural norms, and quality of healthcare could play a pivotal role in boosting the preference for C-sections.
In terms of end-use, hospitals will account for a considerable share of global surgical site infection control market during the forecast period 2022-2028. An increased likelihood of hospital-acquired infection through bloodborne pathogen transmission will force companies to invest in the portfolio. Hospitals are likely to invest in efficient control systems, including disinfectants and surgical gloves. Considering that SSIs represent a significant economic and clinical burden on the healthcare system, leading companies are likely to prioritize control mechanisms.
With respect to region, North America surgical site infection control market share will expand on account of rising cases of deep incisional SSI and superficial incisional SSIs. The U.S. CDC has developed guidelines for the prevention of SSI amidst increasing diabetic population, aging and malnutrition. Recent developments are likely to play a pivotal role in mitigating the risk of SSIs across the region.
Global surgical site infection control market outlook will be propelled through the presence of a host of companies, including Johnson & Johnson, 3M, Belimed AG, Becton, Dickinson and Company, Kimberly-Clark Corporation, Getinge Group, Steris Corporation, Sotera Health and bioMerieux SA, among others. Both well-established players and new entrants are expected to bolster their wide portfolio with investments in innovations, R&D activities and mergers & acquisitions.
For instance, in November 2020, Johnson & Johnson announced that Plus Sutures was recognized for minimizing the risk of surgical site infections to patients. With soaring cases of SSIs in England, the company claims the product will provide antibacterial protection and inhibit bacterial colonization.
With SSI being one of the most prevalent hospital-acquired infections, the spread of the coronavirus escalated the challenges faced in the global economy. The WHO has recommended droplets and contact precautions during the care of suspected COVID-19 patients. The use of surgical masks and disinfectants witnessed an upsurge, boding well for the market forecast. The post-COVID outlook of SSI control market will be robust across North America, Europe and Asia Pacific following the rise in healthcare budget.
At the time when healthcare organizations and other stakeholders advocate the use of personal protective equipment (PPE), SSI control mechanisms will further gain impetus. Likewise, the evolution of healthcare standards and infrastructure will drive market growth.
Market, by Product
Market, by Surgery/Procedure
Market, by Type of Infection
Market, by End-use
The above information is provided for the following regions and countries: